HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?

Amar MJ, D’Souza W, Turner S et al (2010) 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther 334:634–641

Amar MJ, Sakurai T, Ikuta SA et al (2015) A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice. J Pharmacol Exp Ther 352:227–235

Bielicki JK, Zhang H et al (2010) A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 51:1496–1503

Birner-Gruenberger R, Schittmayer M, Holzer M, Marsche G (2014) Understanding high-density lipoprotein function in disease: recent advances in proteomics unravel the complexity of its composition and biology. Prog Lipid Res 56:36–46

Bloedon LT, Dunbar R, Duffy D et al (2008) Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 49:1344–1352

Bocharov AV, Wu T, Baranova IN et al (2016) Synthetic amphipathic helical peptides targeting CD36 attenuate lipopolysaccharide-induced inflammation and acute lung injury. J Immunol 197:611–619

Bourdi M, Amar M, Remaley AT, Terse PS (2018) Intravenous toxicity and toxicokinetics of an HDL mimetic, Fx-5A peptide complex, in cynomolgus monkeys. Regul Toxicol Pharmacol 100:59–67

Buga GM, Frank JS, Mottino GA et al (2006) D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a western diet. J Lipid Res 47:2148–2160

Buga GM, Frank JS, Mottino GA et al (2008) D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a western diet. J Lipid Res 49:92–205

Capodanno D, Mehran R, Gibson CM, Angiolillo DJ (2018) CSL112, a reconstituted, infusible, plasma-mimetic apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. Expert Opin Investig Drugs 27:997–1005

Chattopadhyay A, Yang X, Mukherjee P et al (2018) Treating the intestine with oral ApoA-I mimetic Tg6F reduces tumor burden in mouse models of metastatic lung cancer. Sci Rep 8:9032

Cheng XX, Zheng YY, Bu P et al (2018) Apolipoprotein E as a novel therapeutic neuroprotection target after traumatic spinal cord injury. Exp Neurol 299:97–108

Dai C, Yao X, Keeran KJ et al (2012) Apolipoprotein A-I attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony-stimulating factor-dependent mechanism. Am J Respir Cell Mol Biol 47:186–195

Datta G, White CR, Dashti N, Chaddha M, Palgunachari MN, Gupta H, Handattu SP, Garber DW, Anantharamaiah GM (2010) Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide Ac-hE18A-NH(2). Atherosclerosis 208:134–141

Datta G, Gupta H, Zhang Z, Mayakonda P, Anantharamaiah GM, White CR (2011) HDL mimetic peptide administration improves left ventricular filling and cardiac output in lipopolysaccharide-treated rats. J Clin Exp Cardiol 22:172

DeLeve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS (2008) Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol 173:993–1001

Duffy D, Rader DJ (2009) Update on strategies to increase HDL quantity and function. Nat Rev Cardiol 6:455–463

Easton R, Gille A, D’Andrea D, Davis R, Wright SD, Shear C (2014) A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J Clin Pharmacol 54:301–310

Fazio S, Linton MF (2010) High-density lipoprotein therapeutics and cardiovascular prevention. J Clin Lipidol 4:411–419

Georgila K, Vyrla D, Drakos E (2019) Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer. Cancers 11:1097

Getz GS, Wool D, Reardon CA (2010) HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders. Curr Pharm Des 16:3173–3184

Ghosal K, Stathopoulos A, Thomas D, Phenis D, Vitek MP, Pimplikar SW (2013) The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer’s disease-like pathological features. Neurodegener Dis 12:51–58

Gibson CM, Kerneis M et al (2019) The CSL112-2001 trial: safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-mimetic apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Am Heart J 208:81–90

Gille A, Wright S, Easton R, Shear C (2013) Infusion of CSL112, a novel formulation of human apolipoprotein A-I, in healthy subjects removes tissue cholesterol and directs its clearance. Eur Heart J 34:1947

Gille A, Easton R et al (2014) CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler Thromb Vasc Biol 34:2106–2114

Gille A, D’Andrea D et al (2018) CSL112 (apolipoprotein A-I [human]) enhances cholesterol efflux similarly in healthy individuals and stable atherosclerotic disease patients. Arterioscler Thromb Vasc Biol 38:953–963

Gkouskou KK, Ioannou M, Pavlopoulos GA et al (2016) Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis. Oncogene 35:2496–2505

Gou S, Wang L, Zhong C et al (2020) A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE−/− mice. Br J Pharmacol 177:4627–4644

Gupta H, Dai L, Datta G et al (2005) Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 97:236–243

Hafiane A, Bielicki JK, Johansson JO, Genest J (2015) Novel Apo E-mimetic ABCA1 agonist peptide (CS-6253) promotes reverse cholesterol transport and induces formation of prebeta-1 HDL in vitro. PLoS ONE 10:e0131997

Handattu SP, Garber DW et al (2009) Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer’s disease. Neurobiol Dis 34:525–534

Handattu SP, Nayyar G, Garber DW et al (2013) Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis 227:58–64

Hoane MR, Kaufman N, Vitek MP, McKenna SE (2009) COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain. J Neurotrauma 26:121–129

Ibanez B, Giannarelli C, Cimmino G et al (2012) Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 220:72–77

Jonas A, Phillips MC (2008) Lipoprotein structure. In: Vance DE, Vance JE (eds) Biochemistry of lipids, lipoproteins and membranes, 5th edn. Elsevier, pp 485–506

Kallend DG, Reijers JA et al (2016) A single infusion of MDCO-216 (ApoA-1 milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease. Eur Heart J Cardiovasc Pharmacother 2:23–29

Karalis I, Jukema JW (2018) HDL mimetics infusion and regression of atherosclerosis: is it still considered a valid therapeutic option? Curr Cardiol Rep 20:66

Kempen HJ, Asztalos BF et al (2016) High-density lipoprotein subfractions and cholesterol E_ux capacities after infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in healthy volunteers and stable coronary artery disease patients. Arter Thromb Vasc Biol 36:736–742

Kootte RS, Smits LP, van der Valk FM et al (2015) Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res 56:703–712

Kruger AL, Peterson S, Turkseven S, Kaminski PM, Zhang FF, Quan S, Wolin MS, Abraham NG (2005) D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 111:3126–3134

Kwon WY, Suh GJ, Kim KS et al (2012) 4F, apolipoprotein AI mimetic peptide, attenuates acute lung injury and improves survival in endotoxemic rats. J Trauma Acute Care Surg 72:1576–1583

Laskowitz DT, Lei B, Dawson HN et al (2012) The apoE-mimetic peptide COG1410 improves functional recovery in a murine model of intracerebral haemorrhage. Neurocrit Care 16:316–326

Laskowitz DT, Wang H et al (2017) Neuroprotective pentapeptide CN-105 is associated with reduced sterile inflammation and improved functional outcomes in a traumatic brain injury murine model. Sci Rep 7:46461

Lei B, James ML, Liu J et al (2016) Neuroprotective pentapeptide CN-105 improves functional and histological outcomes in a murine model of intracerebral haemorrhage. Sci Rep 6:34834

Leman LJ, Maryanoff BE, Ghadiri MR (2014) Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J Med Chem 57:2169–2196

Li X, Peng J, Pang J et al (2018) Apolipoprotein E-mimetic peptide COG1410 promotes autophagy by phosphorylating GSK-3beta in early brain injury following experimental subarachnoid hemorrhage. Front Neurosci 12:127

Lowenstein CJ, Cameron SJ (2010) High-density lipoprotein metabolism and endothelial function. Curr Opin Endocrinol Diabetes Obes 17:166–170

Lund-Katz S, Phillips MC (2010) High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell Biochem 51:183–227

Marinho AT, Lu H, Pereira SA et al (2019) Anti-tumorigenic and platinum-sensitizing effects of apolipoprotein A1 and apolipoprotein A1 mimetic peptides in ovarian cancer. Front Pharmacol 9:1524

Marsche G (2015) It’s time to reassess the high-density lipoprotein (HDL) hypothesis: CSL112, a novel promising reconstituted HDL formulation. J Am Heart Assoc 4:e002371

McAdoo JD, Warner DS et al (2005) Intrathecal administration of a novel apoE-mimetic therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury. Neurosci Lett 381:305–308

McGrath K, Li X, Twigg SM, Heather AK (2020) Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice. PLoS One 15:e0226931

Mendez AJ (2010) The promise of apolipoprotein AI mimetics. Curr Opin Endocrinol Diabetes Obes 17:171–176

Mendez-Fernandez Y, Major A (2010) Sizing up stability: combination therapy with Apo-AI peptide mimetics and statins in systemic lupus erythematosus-mediated atherosclerosis. Arthritis Res Ther 12:139

Meriwether D, Sulaiman D, Volpe C et al (2019) Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model. J Clin Invest 129:3670–3685

Montoliu-Gaya L, Mulder SD, Herrebout MAC, Baayen JC, Villegas S, Veerhuis R (2018) Abeta-oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti-Abeta single chain variable fragment in combination with an apoE mimetic peptide. Mol Cell Neurosci 89:49–59

Moreira RS, Irigoyen M, Sanches TR et al (2014) Apolipoprotein A-I mimetic peptide 4F attenuates kidney injury, heart injury, and endothelial dysfunction in sepsis. Am J Physiol Regul Integr Comp Physiol 307:R514–R524

Nandedkar SD, Weihrauch D, Xu H et al (2011) D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J Lipid Res 52:499–508

Nankar SA, Pande AH (2013) Physicochemical properties of bacterial pro-inflammatory lipids influence their interaction with apolipoprotein-derived peptides. Biochim Biophys Acta 1831:853–862. https://doi.org/10.1016/j.bbalip.2013.01.006

Nankar SA, Bulani Y, Sharma SS, Pande AH (2020) ApoE-mimetic peptides attenuated diabetes-induced oxidative stress and inflammation. Protein Pept Lett 27:193–200

Navab M, Anantharamaiah GM, Reddy ST et al (2004) Oral D-4F causes formation of pre-{beta} high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109:3215–3220

Navab M, Anantharamaiah GM, Reddy ST et al (2005) An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25:1932–1937

Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM (2008) Apo A-1 mimetic peptides as atheroprotective agents in murine models. Curr Drug Targets 9:204–209

Navab M, Shechter I, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM (2010) Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 30:164–168

Nowacki TM, Remaley AT, Bettenworth D et al (2016) The 5A apolipoprotein A-I (apoA-I) mimetic peptide ameliorates experimental colitis by regulating monocyte infiltration. Br J Pharmacol 173:2780–2792

Oehler B, Kloka J, Mohammadi M, Ben-Kraiem A, Rittner HL (2020) D-4F, an ApoA-I mimetic peptide ameliorating TRPA1-mediated nocifensive behaviour in a model of neurogenic inflammation. Mol Pain 16:1744806920903848

Ou J, Ou Z, Jones DW et al (2003) L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107:2337–2341

Pang J, Chen Y, Kuai L et al (2017) Inhibition of blood-brain barrier disruption by an apolipoprotein E-mimetic peptide ameliorates early brain injury in experimental subarachnoid hemorrhage. Transl Stroke Res 8:257–272

Park SW, Lee EH, Lee EJ et al (2013) Apolipoprotein A1 potentiates lipoxin A4 synthesis and recovery of allergen-induced disrupted tight junctions in the airway epithelium. Clin Exp Allergy 43:914–927

Peng M, Zhang Q, Liu Y et al (2020) Apolipoprotein A-I mimetic peptide L-4F suppresses granulocytic-myeloid-mimetic suppressor cells in mouse pancreatic cancer. Front Pharmacol 11:576

Peterson SJ, Kim DH, Li M et al (2009) The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res 50:1293–1304

Reijers JAA, Kallend DG et al (2017) MDCO-216 does not induce adverse immunostimulation, in contrast to its predecessor ETC-216. Cardiovasc Drugs Ther 31:381–389

Ribaric S (2018) Peptides as potential therapeutics for Alzheimer’s disease. Molecules 23:283

Rivas-Urbina A, Rull A, Aldana-Ramos J et al (2020) Subcutaneous administration of apolipoprotein J-mimetic mimetic peptide d-[113-122]apoJ improves LDL and HDL function and prevents atherosclerosis in LDLR-KO mice. Biomolecules 10:829

Shah PK (2007) Emerging HDL-based therapies for atherothrombotic vascular disease. Curr Treat Options Cardiovasc Med 9(1):60–70

Sharifov OF, Nayyar G, Garber DW et al (2011) Apolipoprotein E mimetics and cholesterol-lowering properties. Am J Cardiovasc Drugs 11:371–381

Sharma S, Umar S, Potus F et al (2014) Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 130:776–785

Singh K, Chaturvedi R, Barry DP et al (2011) The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling proinflammatory cytokine expression and disease activity in murine models of colitis. J Biol Chem 286:3839–3850

Skaggs BJ, Hahn BH, Sahakian L, Grossman J, McMahon M (2010) Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFR beta, chemotaxis and TNF alpha production. Clin Immunol 137:147–156

Spillmann F, Schultheiss HP, Tschope C, Van Linthout S (2010) High-density lipoprotein-raising strategies: update. Curr Pharm Des 16:1517–1530

Su F, Kozak KR, Imaizumi S et al (2010) Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA 107:19997–20002

Su F, Anantharamaiah GM, Palgunachari MN et al (2020) Bovine HDL and dual domain HDL-mimetic peptides inhibit tumor development in mice. J Cancer Res Ther Oncol 8:101

Suematsu Y, Kawachi E, Idemoto Y et al (2019) Anti-atherosclerotic effects of an improved apolipoprotein A-I mimetic peptide. Int J Cardiol 297:111–117

Tabet F, Remaley AT, Segaliny AI et al (2010) The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 30:246–252

Tanaka S, Couret D, Tran-Dinh A et al (2020) High-density lipoproteins during sepsis: from bench to bedside. Crit Care 24:134

Tardif JC, Gregoire J et al (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297:1675–1682

Tardif JC, Ballantyne CM et al (2014) Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 35:3277–3286

Tsujita M, Wolska A, Gutmann DAP, Remaley AT (2018) Reconstituted discoidal high-density lipoproteins: bioinspired nanodiscs with many unexpected applications. Curr Atherosclerosis Rep 20(12):59–65. https://doi.org/10.1007/s11883-018-0759-1

Tu TM, Kolls BJ et al (2017) Apolipoprotein E mimetic peptide, CN-105, improves outcomes in ischemic stroke. Ann Clin Transl Neurol 4:246–265

Van Lenten BJ, Wagner AC, Anantharamaiah GM et al (2002) Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106:1127–1132

Van Lenten BJ, Wagner AC, Navab M et al (2004) D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 110:3252–3258

Van Linthout S, Spillmann F, Schultheiss HP, Tschope C (2010) High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr Pharm Des 16:1504–1516

Vucic E, Rosenson RS (2011) Recombinant high-density lipoprotein formulations. Curr Atheroscler Rep 13:81–87

Wang H, Durham L, Dawson H et al (2007) An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer’s disease pathology following closed head injury: evidence of pharmacogenomic interaction. Neuroscience 144:1324–1333

Watson CE, Weissbach N, Kjems L et al (2011) Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 52:361–373

Wei J, Zheng M, Liang P, Wei Y, Yin X, Tang Y, Xue Y (2013) Apolipoprotein E and its mimetic peptide suppress Th1 and Th17 responses in experimental autoimmune encephalomyelitis. Neurobiol Dis 56:59–65

Wolska A, Lo L, Sviridov DO et al (2020) A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides. Sci Transl Med 12:eaaw7905

Xu Y, Liu H, Liu M, Li F, Liu L, Du F, Fan D, Yu H (2016) A human apolipoprotein E mimetic peptide reduces atherosclerosis in aged apolipoprotein E null mice. Am J Transl Res 8:3482–3492

Yang N, Tian H, Zhan E et al (2019) Reverse-D-4F improves endothelial progenitor cell function and attenuates LPS-induced acute lung injury. Respir Res 20:131

Yao X, Dai C, Fredriksson K et al (2011) 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol 186:576–583

Ying R, Yuan Y, Qin YF et al (2013) The combination of L-4F and simvastatin stimulate cholesterol efflux and related proteins expressions to reduce atherosclerotic lesions in apoE knockout mice. Lipids Health Dis 12:180

Zhang Z, Datta G, Zhang Y et al (2009) Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol Heart Circ Physiol 297:H866–H873

Zhao W, Du F, Zhang M, Sun S, Yu H, Fan D (2011) A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity. Exp Biol Med 236:1468–1476